

APPROVED  
by Decree #5 of the Foundation  
for Cancer Research Support  
December 12, 2018

# Request for Proposals

Research projects competition funded jointly by the NPO “Foundation for Cancer Research Support” (RakFond) and SciStoreLab, LLC

**RFP Code:** 2018-02

**First Published:** December 12, 2018

Last Updated: December 12, 2018

Please visit [www.rakfond.org/rfp-2018-02-en/](http://www.rakfond.org/rfp-2018-02-en/) for the most up-to-date version of this RFP.



**Foundation for Cancer Research Support  
(RakFond)**

Rochdelskaya str. 15, bld. 17-18, room III  
Moscow, 123022

Russia

[www.rakfond.org/en](http://www.rakfond.org/en)

**SciStoreLab, LLC**

Skolkovo Innovation Center  
Lugovaya str. 4, bld. 9, room 2

Moscow 143026

Russia

[www.sci-store.ru](http://www.sci-store.ru)

## Part I. Overview Information

<b>Funding Program Title</b>	Research projects competition funded jointly by the NPO “Foundation for Cancer Research Support” (RakFond) and SciStoreLab, LLC
<b>Funding Program Aim</b>	<p>The aim of this funding program is to provide support to beginning and established scientists based in Russia to conduct fundamental and exploratory scientific research in the area of molecular and cellular interaction mechanisms between tumors and the immune system.</p> <p>Application submissions for projects in oncoimmunology, immunotherapy, immunoprophylaxis, immunodiagnostics, and immune cell gene therapy will be considered.</p> <p>Applications in the area of veterinary research will not be accepted for this competition.</p> <p>This funding program aims at supporting promising research projects and promoting research in oncology.</p>
<b>Eligibility</b>	Scientist / researcher working full- or part- time (no less than 50%) in an organization conducting research in oncology based in Russia.
<b>RFP Code</b>	2018-02
<b>Key Dates</b>	<p>Posted Date: December 12, 2018</p> <p>Open Date: December 12, 2018</p> <p>Application Due Date: February 01, 2019</p> <p>Formal Compliance Review: February 15, 2019</p> <p>Scientific Review: March 22, 2019</p> <p>Notice of Award: before or on April 15, 2019</p> <p>Final Report: no later than 2 months after project completion date</p>
<b>Award Description</b>	<ol style="list-style-type: none"> <li>1. Reagents / consumables from SciStoreLab’s catalogue with the total value of not exceeding 150 000 (one hundred and fifty thousand) rubles; price list included in Section II.VIII of this RFP.</li> <li>2. Up to 100 000 (one hundred thousand) rubles funding from RakFond for acquiring additional consumables required for the realization of the project and/or conducting the research.</li> </ol>

	<p>Award cannot be used for salary or any other compensation of the winner.</p> <p>Award Term: up to 1 year; no-cost extension of up to 3 months can be provided in exceptional cases only.</p> <p>Number of winners: one (individual).</p>
<b>Applicant Registration</b>	<p>Registration before January 31, 2019 is required, early registration is highly recommended.</p> <p>Register at: <a href="http://www.rakfond.org/rfp-2018-02-registration/">www.rakfond.org/rfp-2018-02-registration/</a></p>
<b>Technical Point of Contact</b>	<a href="mailto:grant@rakfond.org">grant@rakfond.org</a>
<b>Submission</b>	<p>Application and scans of supporting documents must be sent by email by Application Due Date.</p> <p>Winner must send application documents originals to RakFond no later than 7 days after the results are announced.</p>
<b>Application Submission Email</b>	<a href="mailto:grant@rakfond.org">grant@rakfond.org</a>
<b>Documents Mailing Address</b>	<p><b>NPO “Foundation for Cancer Research Support”</b>  Rochdelskaya str. 15, bld. 17-18, 3rd floor, room III, Moscow, 123022, Russia</p>
<b>Program Solicitation Website</b>	<a href="http://www.rakfond.org/rfp-2018-02-en/">www.rakfond.org/rfp-2018-02-en/</a>

# Table of Content

<b>Part I. Overview Information</b>	<b>2</b>
<b>Part II. Full Text of the RFP</b>	<b>6</b>
Section I. Funding Program Description	6
1. Background	6
2. Objectives	6
3. Scope	6
Section II. Award Information	7
1. Summary	7
2. Terms & Conditions	7
A. Responsible Conduct of Research	7
B. Award: Transfer, Use and Restrictions	8
C. Submission of Change Requests	8
D. Requests for Budget Changes or Extensions	8
E. Changes in Research Focus and Project Scope	9
F. Institution Transfer	9
G. Reporting	9
H. Post-Award Reporting Obligation	10
I. Publications, Other Public Release of Results, and Acknowledgments	10
J. Intellectual Property Rights	10
Section III. Eligibility Information	11
1. Eligible Applicants	11
A. Eligible Organizations	11
B. Foreign Participation	11
C. Registration	11
D. Eligible Individuals	12
2. Co-funding	13
3. Additional Information on Eligibility	13
A. Number of Applications	13
Section IV. Application and Submission Information	14
1. Obtaining an Application Package	14
2. Content and Form of Application Submission	14
3. Submission Dates and Times	15
4. Other Requirements	15
A. Application Changes	15
Section V. Application Review Information	16
1. Review Criteria	16
2. Review and Selection Process	17
3. Anticipated Announcement and Award Dates	18
Section VI. Award Transfer Information	19
1. Additional Administrative Requirements	19

2. Award Transfer to the Winner	19
3. Reporting	19
Section VII. RakFond's Contacts	20
Section VIII. Other Information	21

# Part II. Full Text of the RFP

## Section I. Funding Program Description

### 1. Background

The Foundation for Cancer Research Support (RakFond) is a non-profit organization whose main tasks include: financing research and development activities, development of new methods and tools for the prevention, diagnostics and treatment of cancer, promoting the development and improvement of research and scientific activities of research institutions, scientific centers, oncological hospitals, and individual specialists in the field of oncology. The Foundation was founded in 2017 and operates on the territory of the Russian Federation. For more information, visit [www.rakfond.org/en/](http://www.rakfond.org/en/).

This funding program is conducted jointly with SciStoreLab, LLC (<http://www.sci-store.ru>)

SciStoreLab, LLC is a young Russian dynamically developing biotechnology company specializing in development and production of reagents for scientific research in the areas of cell technologies, regenerative medicine, and tissue engineering.

### 2. Objectives

The overall goals of this funding program are:

- 2.1. To promote research in oncology;
- 2.2. To provide effective instruments of support of research projects, including those embedded into larger research programs;
- 2.3. To assist scientists and researchers with achieving publishable results and advancing their research projects.

### 3. Scope

Application submissions for funding research projects (experimental research) in oncology with focus on oncoimmunology, immunotherapy, immunoprophylaxis, immunodiagnostics, and immune cell gene therapy are accepted from individual scientists and researchers.

Applications in the area of veterinary research will not be accepted for this competition.

## Section II. Award Information

### 1. Summary

<b>Award Description</b>	Winner receives funding and reagents / consumables to conduct the research project recognized as the top-ranked on the basis of its scientific expert reviewing.
<b>Anticipated Number of Awards</b>	A single winner (individual) is expected contingent on a submission of meritorious applications.
<b>Award Budget</b>	<ol style="list-style-type: none"><li>1. Funding of up to 100 000 (one hundred thousand) rubles. Application budget must reflect the actual needs of the proposed project. The final award budget may be subject to negotiation.</li><li>2. Reagents / consumables from SciStoreLab's catalogue with the total value of not exceeding 150 000 (one hundred and fifty thousand) rubles (see Section II.VIII). The final list may be subject to negotiation.</li></ol>
<b>Award Project Period</b>	<p>The scope of the proposed project should determine the project period. The maximum Award Period is 12 months.</p> <p>In special cases, RakFond may allow a single up to 3-month no-cost extension request, which will be approved or disapproved at its discretion. (See Section II.2.D "Terms &amp; Conditions. Request for Budget Changes or Extensions.")</p>

### 2. Terms & Conditions

Award Recipient (Winner) and Award Recipient's Organization<sup>1</sup> (ARO) accept the following Terms and Conditions:

#### A. Responsible Conduct of Research

1. The project must be conducted according to the highest scientific and ethical standards and in compliance with all applicable laws and regulations and with the policies of ARO. To the extent policies of ARO conflict with these Terms and Conditions and/or RakFond's policies, these Terms and Conditions will prevail.
2. Upon request of RakFond, the Winner must provide copies of documentation of ARO's research project approval prior to commencing the project, if applicable.

---

<sup>1</sup> Here and further in this document ARO means an organization mentioned in Part I of this RFP, where the Winner works full- or part-time.

3. Upon request of RakFond, the Winner must provide copies of documentation of ARO's approval for research on animal subjects prior to commencing research, if applicable.

#### B. Award: Transfer, Use and Restrictions

4. The funds will be transferred to the ARO or the Winner directly. The final decision regarding the manner of funds' transfer will be made by RakFond after the competition results announcement with consideration of Winner's position.
5. Reagents / consumables will be transferred to the Winner directly by SciStoreLab, LLC.
6. The Winner is not permitted to transfer the funds and/or the reagents to any other person and/or organization.
7. The funds must be used solely as detailed in the application and its budget.
8. The funds can be used exclusively for acquiring complementary consumables, which are necessary for conducting the research project, which was stated by the Winner in the application.
9. Indirect or travel expenditures are not allowed. Funds cannot be used to pay salaries. No funds can be used for subcontracts and outsourced research. The research must be performed by the Winner personally.
10. Funds cannot be used for expenditures incurred prior to the first day of the Award Period or after the last day of the Award Period. No additional expenses may be paid from received funds after RakFond received the Winner's final expenditure report or after any unexpended funds were returned to RakFond.
11. At the end of the Award Period, any unexpended funds and any funds expended inconsistently with the proposed project must be returned to RakFond.

#### C. Submission of Change Requests

12. All change requests related to the project funding must be initiated by sending an email to: [grant@rakfond.org](mailto:grant@rakfond.org).

#### D. Requests for Budget Changes or Extensions

13. The Winner may move funds of up to 25% of the total budget between budget categories of the approved project budget without prior written approval of RakFond. Notwithstanding the foregoing, indirect and travel costs cannot be introduced, neither can salaries and/or subcontracts and outsourced research.
14. Budget changes of greater than 25% between budget categories or adding new budget categories must be approved in writing by RakFond before expenditure of funds. The Winner must submit a re-budget request with a detailed justification of the proposed change by sending an email to: [grant@rakfond.org](mailto:grant@rakfond.org).
15. In exceptional cases, RakFond may allow a single up to 3-month no-cost project extension, which will be approved or disapproved at its discretion with the reasons for the decision. The extension request, an updated financial expenditure and progress report, and a detailed explanation of why the request is being made must be emailed to: [grant@rakfond.org](mailto:grant@rakfond.org).
16. Any request for a no-cost extension or budget change must be made at least 60 days prior to the expiration of the Award Period. Requests received after that date will not be accepted and will automatically be disapproved.



17. If a no-cost extension is granted by RakFond, the Winner must submit final reports within two months after the actual project completion date.

#### E. Changes in Research Focus and Project Scope

18. Major changes in the overall research topic, approaches and methods are not allowed. However, some changes in the specific goals of the project may be allowed with prior written consent from RakFond. Any request for changes must be sent by email to: [grant@rakfond.org](mailto:grant@rakfond.org). An approval must be received prior to performing any changes to the project. RakFond will approve or disapprove the request at its discretion and will provide reasons for the decision.

#### F. Institution Transfer

19. If the Winner accepts an appointment at another institution during the Award Period, and desires to have the funds transferred to the new organization, the Recipient must submit a fund transfer request by email to: [grant@rakfond.org](mailto:grant@rakfond.org) at least 30 days before the anticipated date of transfer, including a written confirmation from the new organization, stating a commitment to support the research project, signed by new organization's Authorized Representative . Subject to RakFond's written approval and at its sole discretion, the funds may be transferred provided arrangements satisfactory to RakFond are implemented to continue the research project in a manner in which it was originally approved by RakFond. Any transfer must be approved in writing by RakFond before any such transfer takes place. Upon approval of a transfer of the funds to a new organization, the ARO must return any unexpended funds and any funds expended inconsistent with the project to RakFond. The new organization will agree to comply with these Terms and Conditions. RakFond will make arrangements to provide remaining funds to the new organization.
20. If the Winner is unable or not permitted to transfer the funds to a new organization, the Winner and the ARO will relinquish the funding and any unexpended funds or funds expended inconsistent with the research project must be returned to RakFond.
21. If during the Award Period the Winner relinquishes employment or affiliation with the ARO, or part-time employment is reduced below 50% of time, the Winner must submit a written report to RakFond about these changes no later than 3 (three) days after becoming familiar with those changes. RakFond will be considering possibilities of continuing support of the project on case-by-case basis.

#### G. Reporting

22. The final report consisting of expenditure (financial) and project results (technical) reports is due 2 (two) months after project conclusion date. It is the responsibility of the Winner to submit the final report in a timely manner. RakFond may contact appropriate persons in the ARO to ensure the project results reports and expenditure reports are received as required.
23. Noncompliance with any of these Terms and Conditions, including failure to submit project results and/or expenditure reports, may result in the withholding of payment on other funding programs of RakFond in effect at the ARO, or on RakFond's funding programs that may be awarded in the future, or such other action deemed appropriate by RakFond.

## H. Post-Award Reporting Obligation

24. After the final report, the Winner can be asked to respond to RakFond's requests for information on his/ her career progress following the Award Period and may be asked to provide his/her current Curriculum Vitae and/or publication list. The information may be used for program evaluation and alumni communications. The Winner understands that this obligation survives the Award Period and that he/she has an obligation to provide this information during 5 (five) years after the project completion date.
25. RakFond reserves the right to include information relating to this Award in its periodic reports, annual reports, awardee directory, publicly accessible databases of funded research projects, or in any other materials issued by or on behalf of RakFond or its affiliates.

## I. Publications, Other Public Release of Results, and Acknowledgments

26. RakFond strongly encourages the Winner to submit the results of funded research project for publication or other public release. In the event the Winner's results are published or otherwise publicly released either during or after the Award Period, the Winner will provide RakFond with a copy of such publication or public release.
27. The Winner and ARO agree that all abstracts, publications, presentations, and other intellectual property resulting from research supported by this funding must contain the acknowledgment, "This work was (partially) funded by the NPO "Foundation for Cancer Research Support" and SciStoreLab, LLC under funding program 2018-02". Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of RakFond and/or SciStoreLab, LLC."

## J. Intellectual Property Rights

28. RakFond and SciStoreLab, LLC will have no intellectual property rights or other rights in or to data collected or scientific discoveries made through any project funded by program. RakFond encourages its recipient and the sponsoring institutions to report to RakFond any inventions, discoveries, or intellectual properties that result from the support of the research.

## Section III. Eligibility Information

**RakFond reserves the right to evaluate and determine applicants' eligibility based on the information and justifications included in the application materials, publicly available information, and any other additional requests for information, if necessary.**

### 1. Eligible Applicants

#### A. Eligible Organizations

Applicants from any domestic public or private institutions of higher education, clinics, hospitals, research centers, non-profit or for-profit organizations, whose activities involve research in the area of oncology may be eligible to receive the Award.

Potential applicants should be prepared to establish eligibility of their organization to receive and administer funding, and RakFond reserves the right to reject application if an organization is determined not to satisfy eligibility criteria for this funding program. RakFond urges potential applicants to consider the following eligibility considerations:

- What is the nature of the research and business that your organization performs? Are they related to oncology and fit within this RFP's objectives and scope?
- Does your organization conduct scientific research?
- Has your organization applied to and/or been funded to do oncology related research by any Federal agency or private foundation?
- Have the results of any oncology related research papers been published by researchers from your organization?
- Is your organization professionally responsible for the research?
- Where physically is the proposed research to be conducted?

Forms and documentation submitted to RakFond must reflect the name of the Authorized Representative (AR), with the appropriate authority to sign and submit documentation on the organization's behalf. AR's signature certifies commitment of the organization to support a project that RakFond is being asked to fund, that the organization will be accountable for the appropriate use of funds (in case the funds are transferred to the organization's account), and that the organization complies with required licenses and certifications, which are necessary for proposed experiment and/or research conduct, and accepts the terms and conditions of RakFond's funding, which are described in the Request for Proposals .

#### B. Foreign Participation

Researchers based in foreign institutions and international organizations, including public or private non-profit or for-profit organizations, are NOT ELIGIBLE to apply for this funding program. Applicants must be affiliated with eligible domestic organizations only; however, an applicant may be a non-Russian citizen.

Within this funding program RakFond may support projects with a part performed outside of Russia either by the Winner or by researchers from the Winner's research group,

#### C. Registration

All applicants will have to complete one-time registration process prior to submitting any application. Registration will help RakFond to make a preliminary assessment of applicant's eligibility.

Applicants are strongly encouraged to submit a registration form as soon as possible. This will help RakFond in timely determining Applicant's and the organization's eligibility prior to the final application submission deadline. Applications, for which organizational eligibility cannot be determined by the Formal Compliance Review deadline (February 15, 2019) will be automatically excluded from further consideration.

Registration form must be filled in on-line at: [www.rakfond.org/rfp-2018-02-registration/](http://www.rakfond.org/rfp-2018-02-registration/).

The following information is required to complete the registration form:

#### APPLICANT

1. First Name (required)
2. Middle Name (optional)
3. Last Name (required)
4. Education and scientific degrees (required)
5. Current research appointment and organization (required). Full time or part-time (percentage of time spent on research, if part-time)
6. Primary Email to be used for all communications regarding this application (required)
7. Address (at least one, checked as primary) (required)
8. Phone (at least one, checked as primary) (required)
9. Website (optional)

#### ORGANIZATION(S)

1. Organizational Affiliations (single or multiple) (required)
2. Organization's addresses, both legal and actual (required). A primary organization must be designated, if affiliated with multiple organizations.
3. Website (required)
4. Name of primary organization's Authorized Representative (AR) (required)
5. AR's department and title (required)
6. AR's organizational email (required) and phone (optional)

#### PROJECT

1. Preliminary title (required)
2. Main goals (required)

Technical assistance with the registration form can be obtained by sending an email to: [grant@rakfond.org](mailto:grant@rakfond.org).

#### D. Eligible Individuals

Applicants must meet the following criteria to be eligible to apply:

1. Conduct scientific research in oncology.
2. Work full-time or part-time (no less than 50%) in an organization/institution (oncology laboratory, clinical research setting, or private company, etc.) involved in oncology research.
3. For the research project it is necessary and sufficient to use reagents / consumables from the list given in Section II.VIII and the supplementary funding from RakFond.

## 2. Co-funding

This program does not require co-funding. However, if Award Recipient's Organization commits to providing co-funding, corresponding information should be included in the application.

## 3. Additional Information on Eligibility

### A. Number of Applications

Each scientist / researcher may submit only one proposal for this funding program.

More than one application by different applicants may be submitted from an eligible organization, provided that each application is scientifically distinct.

## Section IV. Application and Submission Information

All applications must be submitted in accordance with the requirements and instructions of this Request for Proposals (RFP). Application form and supporting documents must be submitted in English (except for those listed in paragraph 2 below, which may be submitted in Russian). All application documents must use RakFond's forms and templates, follow RakFond's guidelines, and must be submitted in a timely manner. Incomplete applications and applications submitted after deadlines will be automatically rejected.

### 1. Obtaining an Application Package

Applicants must download application form and templates associated with this funding program from [www.rakfond.org/rfp-2018-02-en/](http://www.rakfond.org/rfp-2018-02-en/). Form and templates contain all necessary instructions, including: required information, page limitations, budget categories, etc.

### 2. Content and Form of Application Submission

Applications should consist of a single PDF file or a set of PDF files containing the following documents assembled in the following order:

1. Cover letter signed by AR **(required) - in Russian or in English**
2. Application form including brief rationale, scientific hypothesis, aim and goals, study design, sufficient resources, detailed budget and study timelines **(5 pages maximum) (required) - in English**
3. Applicant's CV with the list of up to ten selected publications and link to Google Scholar or other relevant profile **(2 pages maximum) (required) - in English**
4. Support letters from the organization, mentor, supervisor, etc. **(optional, but no more than 2 letters up to 2 pages each) - in English**
5. Other supporting documentation **(optional, should not exceed 10 pages) - in Russian or in English**

Formatting requirements:

Render and submit a single PDF file or a set of PDF files named "RFP-2018-02-[Your First Name]-[Your last name]-document index (if applicable)", that precisely follows the guidance of form and templates, and the order above. For example, "RFP-2018-02-Ivan-Petrov".

To ensure maximum protection of your information, please mark all pages of your application, where possible, with the footer "Confidential and Proprietary – Exempt from Disclosure."

Application PDF should be emailed before the submission deadline to: [grant@rakfond.org](mailto:grant@rakfond.org) with the Application PDF file name as the Subject. For example, "RFP-2018-02-Ivan-Petrov".

If the PDF file size exceeds 25 MB, send documentation in separate emails. Name those files "RFP-2018-02-[Your First Name]-[Your last name]-[Addendum (1, 2, 3, etc.)]" and use those names as the Subject.

### 3. Submission Dates and Times

Completed application and all supporting materials must be received via email [grant@rakfond.org](mailto:grant@rakfond.org) before 23:59 (Moscow time) on February 01, 2018. Applications received after this deadline will not be considered.

The Winner must send to RakFond the originals of all documents, which were submitted in the electronic form during the application process, no later than 7 (seven) days after the competition results are announced. Documents must be sent by Express Mail and include Confirmation of Delivery or any other certificate, which confirms receipt of the originals by RakFond.

The originals must be sent to:

**Foundation for Cancer Research Support**

Rochdelskaya str. 15, bld. 17-18, 3rd floor, room III,

Moscow, 123022

If the Winner fails to send the originals within the required period of time, RakFond reserves right to withdraw the award and transfer it to another competition participant with sufficient score.

### 4. Other Requirements

#### A. Application Changes

The applicant must notify RakFond within 3 (three) days by sending an email to [grant@rakfond.org](mailto:grant@rakfond.org) if any of the following condition applies from application submission through award notification:

1. The applicant leaves his/her current position in the organization, changes organizations, or unable to meet the eligibility requirements stated in Section III.1.D.
2. Other significant changes in applicant's career plans or organization's conditions, which may affect goals, research strategy, timeline, and/or budget (organization ceases operation, loses funding, etc.).

If RakFond is notified of any of these changes in after the applicant is notified of an award, RakFond has the right to withdraw the award.

## Section V. Application Review Information

RakFond's core requirements for proposals are:

- Based on world-class science, that has the potential to provide significant advance in cancer research and oncology
- Have goals that are clear, ambitious, and credible
- Yield practical, measurable outcomes
- Employ rigorous methodology
- Will achieve publishable results

Scores are given based on individual merit; applications are not evaluated against one another.

### 1. Review Criteria

A winner will be selected based on the following criteria:

	<b>Explanation</b>	<b>Weight (0-1)</b>
<b>Significance</b>	Does the proposal address an important problem to advance the field? Is there a strong scientific foundation for the proposal? If the goals of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? Is there a high probability of publishing project's research results in high-impact journals?	1
<b>Investigator</b>	Does the applicant have appropriate experience and training? Factors considered include the quality and extent of past education, scientific training, research experience, research originality and productivity.	1
<b>Novelty</b>	Does the application seek to utilize novel concepts, methodologies, instrumentation, or interventions?	0.66
<b>Approach</b>	Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific goals of the project? Have the investigators presented strategies to ensure a robust and unbiased approach? Are potential problems, risks, alternative strategies, and benchmarks for success presented?	0.66



<b>Environment</b>	Are the institutional support, equipment and other resources available to the investigator adequate for the project proposed? Will the project benefit from some unique features of the scientific environment?	0.33
<b>Total Maximum Score</b>		<b>33</b>

RakFond uses a 9-point scale (from 1 to 9, with 9 being the highest mark) for all individual review criteria. Scores for each criterion will be accompanied by the review critique. RakFond expects, that only applications with scores of at least 5 (“good”) for each criterion will be considered for funding.

The table below provides a guide for individual criterion scores:

<b>Criterion Strength</b>	<b>Score</b>	<b>Descriptor</b>
<b>High</b>	9	Exceptional
	8	Outstanding
	7	Excellent
<b>Medium</b>	6	Very Good
	5	Good
	4	Satisfactory
<b>Low</b>	3	Fair
	2	Marginal
	1	Poor

## 2. Review and Selection Process

RakFond employs a rigorous scientific review process to evaluate proposals received in response to RFPs.

Submitted proposals are first evaluated for completeness and formal compliance with an RFP by RakFond and SciStoreLab, LLC. Proposals that comply with the requirements of the RFP will be considered conforming. Only conforming proposals will be evaluated further.

RakFond will assign proposals for scientific review to a minimum of three reviewers.

Once scientific reviews are complete, the reviewers' evaluation reports are forwarded to RakFond. RakFond will review each proposal and associated evaluation reports to ensure that the evaluation reports adequately document the review conducted. It is RakFond's responsibility to ensure that the reviewers have provided sufficient, substantive rationale for their review findings.

RakFond then compiles a full recommendation package, which includes reviews and texts of all of the selectable proposals. The recommendation is sent to the members of the Scientific Advisory Board (SAB). They review the complete evaluation package and give their funding recommendations for each selectable proposal.

Finally, the recommendation package is forwarded to the Board of Directors for the funding approval taking into account SAB's recommendations.

As the result of the competition, RakFond determines 1 (one) Winner and transfers relevant information to SciStoreLab, LLC.

### 3. Anticipated Announcement and Award Dates

After proposal evaluations are complete, applicants will be notified as to whether their proposal was deemed selectable as a result of the review process. Applicants can expect to be notified no later than April 15, 2019, via email to their primary email address on file. Notification may also be sent by email to the Applicant's organization Administrative Representative identified on the proposal Cover sheet. Applicants should ensure that their and their organization's AR primary email addresses on file are updated prior to April 15, 2019.

Applicants should add [grant@rakfond.org](mailto:grant@rakfond.org) to their safe senders list to ensure they receive timely notifications such as document submission notifications, application submission confirmations, etc. If applicants are not receiving notifications, they should check their junk/spam folders first, then contact [grant@rakfond.org](mailto:grant@rakfond.org) for additional assistance.

## Section VI. Award Transfer Information

### 1. Additional Administrative Requirements

None for this RFP.

### 2. Award Transfer to the Winner

At the conclusion of the competition, the funds are transferred to the Winner by RakFond, and the reagents / consumables – by SciStoreLab, LLC. Both organizations act on their own and independently: each organization signs independent contracts with the Winner, as well as is solely responsible for their own contracts and Winner's compliance to the terms and conditions of the contracts and this RFP.

### 3. Reporting

The number and types of technical and financial reports required under the project are specified in Section II.2 "Terms & Conditions", Subsection G.

## Section VII. RakFond's Contacts

RakFond will use email for all technical and administrative correspondence regarding this funding program.

**Email:** [grant@rakfond.org](mailto:grant@rakfond.org)

**Mailing address:**

NPO "Foundation for Cancer Research Support"  
Rochdelskaya str. 15, bld. 17-18, 3rd floor, room III,  
Moscow, 123022  
Russia

**Solicitation Website:** [www.rakfond.org/rfp-2018-02-en/](http://www.rakfond.org/rfp-2018-02-en/)

## Section VIII. Other Information

### SciStoreLab, LLC Price List

		<b>SciStoreLab LLC</b> <b>143026 Russian Federation, Moscow, Territory of the</b> <b>in innovation center Scolkovo, Iugovaya str.4,</b> <b>Building 9, prem. 2</b>			
<b>№</b>	<b>Product</b>	<b>Description</b>	<b>Packing</b>	<b>Cat.N°</b>	<b>Pricing (rubles)</b>
<b>Growth factors, cytokines</b>					
<b>1</b>	<b>Human Albumin</b>	rhAlbumin, human albumin recombinant protein	1 mg	PSP100-1	30 000
<b>2</b>	<b>Human EGF</b>	rhEGF, human epidermal growth factor, recombinant protein	10 µg	PSG130-10	11 000
<b>3</b>	<b>Human Epo</b>	rhEpo, human erythropoietin, recombinant protein	2 µg	PSG110-02	7 000
		rhEpo, human erythropoietin, recombinant protein	10 µg	PSG110-10	14 000

		rhEpo, human erythropoietin, recombinant protein	100 µg	PSG110-50	70 000
<b>4</b>	<b>Human FGF2</b>	rhFGF2, human fibroblast growth factor-2, recombinant protein	10 µg	PSG060-10	11 000
		rhFGF2, human fibroblast growth factor-2, recombinant protein	50 µg	PSG060-50	26 900
<b>5</b>	<b>Human Flt3-Ligand</b>	rhFlt3 Ligand, human FMS-like tyrosine kinase 3 ligand, recombinant protein	2 µg	PSG080-02	5 500
		rhFlt3 Ligand, human FMS-like tyrosine kinase 3 ligand, recombinant protein	10 µg	PSG080-10	14 000
		rhFlt3 Ligand, human FMS-like tyrosine kinase 3 ligand, recombinant protein	50 µg	PSG080-50	40 000
<b>6</b>	<b>Human GM-CSF</b>	rhGM-CSF, human granulocyte-macroph age colony-stimulating factor, recombinant protein	2 µg	PSG030-02	5 500

		rhGM-CSF, human granulocyte-macroph age colony-stimulating factor, recombinant protein	5 µg	PSG030-05	8 000
		rhGM-CSF, human granulocyte-macroph age colony-stimulating factor, recombinant protein	10 µg	PSG030-10	14 000
		rhGM-CSF, human granulocyte-macroph age colony-stimulating factor, recombinant protein	50 µg	PSG030-50	40 000
<b>7</b>	<b>Human HGF 728AA</b>	rhHGF 728AA, human hepatocyte growth factor, recombinant protein	2 µg	PSG190-02	5 500
		rhHGF 728AA, human hepatocyte growth factor, recombinant protein	10 µg	PSG190-10	14 000
		rhHGF 728AA, human hepatocyte growth factor, recombinant protein	50 µg	PSG190-50	40 000

<b>8</b>	<b>Human HGF 723AA</b>	rhHGF 723AA, human hepatocyte growth factor, recombinant protein	2 µg	PSG200-02	5 500
		rhHGF 723AA, human hepatocyte growth factor, recombinant protein	10 µg	PSG200-10	14 000
		rhHGF 723AA, human hepatocyte growth factor, recombinant protein	50 µg	PSG200-50	40 000
<b>9</b>	<b>Human IGF-I</b>	rhIGF-I, human insulin-like growth factor-I, recombinant protein	10 µg	PSG120-10	11 000
<b>10</b>	<b>Human IL-3</b>	rhIL-3, human interleukin-3, recombinant protein	2 µg	PSG160-02	5 500
		rhIL-3, human interleukin-3, recombinant protein	10 µg	PSG160-10	14 000
<b>11</b>	<b>Human IL-4</b>	rhIL-4, human interleukin-4, recombinant protein	2 µg	PSG040-02	5 500
		rhIL-4, human interleukin-4,	10 µg	PSG040-10	14 000



		recombinant protein			
		rhIL-4, human interleukin-4, recombinant protein	100 µg (10 pc * 10 µg)	PSG040-100	120 000
<b>12</b>	<b>Human IL-6</b>	rhIL-6, human interleukin-6, recombinant protein	2 µg	PSG180-02	5 500
		rhIL-6, human interleukin-6, recombinant protein	10 µg	PSG180-10	14 000
		rhIL-6, human interleukin-6, recombinant protein	100 µg	PSG180-100	120 000
<b>13</b>	<b>Human LIF</b>	rhLIF, human leukemia inhibitory factor, recombinant protein	2 µg	PSC010-02	8 000
		rhLIF, human leukemia inhibitory factor, recombinant protein	10 µg	PSC010-10	20 000
<b>14</b>	<b>Human Noggin</b>	rhNog, human noggin, recombinant protein	2 µg	PSG100-02	5 500

		rhNog, human noggin, recombinant protein	10 µg	PSG100-10	14 000
<b>15</b>	<b>Human PIGF</b>	rhPIGF, placental growth factor-1, recombinant protein	2 µg	PSG050-02	5 500
		rhPIGF, placental growth factor-1, recombinant protein	10 µg	PSG050-10	14 000
		rhPIGF, placental growth factor-1, recombinant protein	50 µg	PSG050-50	40 000
<b>16</b>	<b>Human SCF</b>	rhSCF, human stem cell factor, recombinant protein	2 µg	PSG170-02	5 500
		rhSCF, human stem cell factor, recombinant protein	10 µg	PSG170-10	14 000
<b>17</b>	<b>Human TPO</b>	rhTpo, human thrombopoietin, recombinant protein	2 µg	PSG090-02	10 000

		rhTpo, human thrombopoietin, recombinant protein	10 µg	PSG090-10	28 000
		rhTpo, human thrombopoietin, recombinant protein	50 µg	PSG090-50	80 000
<b>18</b>	<b>Human VEGF-A121</b>	rhVEGF-A121, human vascular endothelial growth factor,  Isoform 121, recombinant protein	2 µg	PSG140-02	5 500
		rhVEGF-A121, human vascular endothelial growth factor,  Isoform 121, recombinant protein	10 µg	PSG140-10	14 000
<b>19</b>	<b>Human VEGF-A165</b>	rhVEGF-A165, human vascular endothelial growth factor,  Isoform 165, recombinant protein	2 µg	PSG010-02	5 500
		rhVEGF-A165, human vascular endothelial growth factor,  Isoform 165, recombinant protein	10 µg	PSG010-10	14 000

		rhVEGF-A165, human vascular endothelial growth factor,  Isoform 165, recombinant protein	100 µg	PSG010-100	120 000
<b>20</b>	<b>Human VEGF-A189</b>	rhVEGF-A189, human vascular endothelial growth factor,  Isoform 189, recombinant protein	2 µg	PSG150-02	5 500
		rhVEGF-A189, human vascular endothelial growth factor,  Isoform 189, recombinant protein	10 µg	PSG150-10	14 000
<b>Antibodies</b>					
<b>21</b>	<b>Human c-Myc Tag mAb</b>	anti-c-Myc Tag, mouse monoclonal antibody, 9E10 clone	100 µg	PSM003-100	12 000
<b>22</b>	<b>Human c-Myc Tag mAb Biotinylated</b>	anti-c-Myc Tag, biotinylated mouse monoclonal antibody, 9E11 clone	100 µg	PSM003BN-1 00	18 000
<b>23</b>	<b>GFP Antibody</b>	anti-GFP-IP, Immunoprecipitation protocol using anti-GFP antibody,  2G7 clone	100 µg	PSM002-100	12 000

<b>24</b>	<b>GFP Antibody</b>	anti-GFP-WB, Immunoblotting protocol using anti-GFP antibody, 3A9 clone	100 µg	PSM001	12 000
<b>25</b>	<b>Human IFN-beta Antibody</b>	anti-human IFN-beta antibody, 4-2R1 clone, Immunoblotting/ Immunoprecipitation protocol using antibody, neutralizing	100 µg	PSM004-100	21 000
<b>ELISA</b>					
<b>26</b>	<b>ELISA VEGF-A165</b>	The human vascular endothelial growth factor A-165 ELISA Kit		EHV001-00	45 000
<b>Enzymes</b>					
<b>27</b>	<b>DNase I</b>	Human deoxyribonuclease I, recombinant protein	2000UE	SSF001	9 500
<b>Mediums</b>					
<b>28</b>	Serum-Free Cell Freezing Medium	Serum-Free Cell Freezing Medium for cryopreservation	35 ml	SSM001-35	7 500

